Edition:
United States

Medigene AG (MDG1k.DE)

MDG1k.DE on Xetra

13.26EUR
11:35am EST
Change (% chg)

€1.25 (+10.41%)
Prev Close
€12.01
Open
€12.10
Day's High
€13.26
Day's Low
€12.05
Volume
762,346
Avg. Vol
296,872
52-wk High
€15.24
52-wk Low
€8.53

Latest Key Developments (Source: Significant Developments)

Medigene Sells US-Rights For Veregen, Raises 2017 Guidance
Tuesday, 5 Dec 2017 10:30am EST 

Dec 5 (Reuters) - MEDIGENE AG ::PTA-ADHOC: MEDIGENE AG: MEDIGENE SELLS US-RIGHTS FOR VEREGEN® AND RAISES FINANCIAL GUIDANCE 2017.EXPECTS REVENUES OF EUR 10.5-11.5 M INSTEAD OF EUR 8-10 M AS PREVIOUSLY GUIDED.EXPECTS 2017 EBITDA-LOSS OF EUR 14-15 M INSTEAD OF EUR 16-18 M.EXPECTS 2017 CASH UTILIZATION OF EUR 20-22 M INSTEAD OF EUR 23-27 M.  Full Article

Medigene says 9M immunotherapy revenue 3.4 mln eur
Thursday, 9 Nov 2017 01:30am EST 

Nov 9 (Reuters) - Medigene :Says confirms its financial guidance for 2017.Says 9M revenue from core business immunotherapies (bluebird bio partnership) of eur 3.435 million.Says 9M total revenue eur 7.176 million (9M 2016: eur 7.052 million).Says 9M EBITDA loss increased as planned to eur 10.143 million (9M 2016: eur 9.095 million).  Full Article

Medigene to issue new shares to settle Trianta milestone payment
Thursday, 7 Sep 2017 12:00pm EDT 

Sept 7 (Reuters) - Medigene AG :Announces issuance and number of new shares to settle last Trianta milestone payment.Says 2 million euro milestone payment for achievement of third milestone for Trianta acquisition will be settled by issuance of new shares.Says to issue 182,335 new shares to former contributing shareholders of Medigene Immunotherapies GmbH.Says with this third and final milestone payment, the total purchase price of approx. 10 million euros will have been entirely settled.Says subscribers of new shares agreed to a lockup period of 14 months.  Full Article

Medigene H1 total revenue at EUR 4.9 mln​
Thursday, 3 Aug 2017 01:30am EDT 

Aug 3 (Reuters) - MEDIGENE AG :H1 ‍REVENUE FROM CORE BUSINESS IMMUNOTHERAPIES (BLUEBIRD BIO PARTNERSHIP) AMOUNTS TO EUR2,252 K (6M 2016: EUR0 K)​.‍H1 TOTAL REVENUE OF EUR4,915 K (6M 2016: EUR5,470 K)​.‍CONFIRMATION OF FINANCIAL GUIDANCE 2017​.  Full Article

Medigene submits CTA for its first TCR clinical trial
Monday, 10 Jul 2017 09:35am EDT 

July 10 (Reuters) - MEDIGENE AG :PTA-ADHOC: MEDIGENE AG: MEDIGENE SUBMITS CTA FOR ITS FIRST TCR CLINICAL TRIAL AND ANNOUNCES MILESTONE PAYMENT.EXPECTS TO START THIS TRIAL BY YEAR END 2017.SUBMISSION TRIGGERS FINAL MILESTONE PAYMENT OF EUR 2.0 MILLION FROM MEDIGENE TO FORMER CONTRIBUTING SHAREHOLDERS OF MEDIGENE IMMUNOTHERAPIES GMBH WITHIN NEXT FIVE MONTHS.INTENDS TO SETTLE THIS PAYMENT THROUGH ISSUANCE OF NEW SHARES FROM AUTHORIZED CAPITAL.  Full Article

Medigene sticks with guidance after Q1 operating loss
Thursday, 11 May 2017 01:30am EDT 

May 11 (Reuters) - Medigene AG :Total Q1 revenue of eur 2,609 k.EBITDA loss increased as planned to eur 3,020 k.Cash and cash equivalents of eur 48,045 k on 3/31/2017.Financial guidance for 2017 confirmed.  Full Article

Medigene COO steps down
Thursday, 11 May 2017 01:28am EDT 

May 11 (Reuters) - Medigene AG :Says Dave Lemus steps down as COO and continues cooperation in an advisory role.  Full Article

Medigene says raises 20.7 mln eur in private placement
Friday, 5 May 2017 02:37am EDT 

May 5 (Reuters) - Medigene Ag :Says successfully raises eur 20.7 million in oversubscribed private placement.Says shares were allocated to institutional investors at a price of eur 10.55 per share.Says capital increase represents approximately of 9.7% of currently outstanding shares.  Full Article

Medigene revises collaboration with Mitsui Norin
Thursday, 23 Mar 2017 09:15am EDT 

Medigene AG : Medigene revises collaboration with Mitsui Norin . Today announced a new contractual arrangement with Mitsui Norin Co. Ltd, regarding its drug Veregen . Current manufacturing and supply agreement has been mutually terminated as of March 31, 2017 . Previous agreement has been replaced by a new license agreement covering drug master file (DMF) for Veregen . As a part of arrangement to terminate existing manufacturing and supply agreement, Medigene has agreed to a one-time payment of $1.75 million to Mitsui Norin . Additional payment to Mitsui Norin for up to $0.5 million to reimburse costs of ending production is also expected in course of 2017 .No further financial details regarding new license agreement were disclosed.  Full Article

Medigene FY total revenue increases 43 pct to 9.8 mln euros
Thursday, 23 Mar 2017 02:30am EDT 

Medigene Ag : FY total revenue increases 43 pct to 9.8 million euros ($10.58 million) . Financial guidance for 2016 met . Financial guidance for 2017 reflects Medigene's alignment and continued focus on its core business of immunotherapies . 2017 revenue: planned total revenue in 2017 between 8 - 10 million euros . 2017 projected EBITDA loss of 16 - 18 million euros . For 2017 Medigene anticipates cash utilization of between 23 - 27 million euros, partly due to non-recurring effects such as investments in laboratory infrastructure . FY net loss for year was reduced by 27 pct to 9.492 million euros (2015: 12.999 million euros) .Company has sufficient financial resources to fund business operations well beyond forecast horizon of two years.  Full Article

BRIEF-Medigene, RXi To Collaborate On Therapeutic T Cells

* MEDIGENE COLLABORATES WITH RXI PHARMACEUTICALS TO FURTHER SHARPEN ITS THERAPEUTIC T CELLS